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ABSTRACT 
 
Objective: Thyroid cancer is the most common endocrine malignancy and patients 
presenting with thyroid nodules often undergo surgery solely for diagnostic purposes. 
The goal of our study was to examine the accuracy of Elastic Scattering Spectroscopy 
(ESS) in distinguishing between benign and malignant thyroid nodules in fresh ex vivo 
specimens and to design an in vivo ESS probe and device, manufacture it and conduct a 
clinical trial.  
vi 
Methods:  Patients already undergoing thyroidectomy surgery were consented for the ex 
vivo study. ESS data was obtained from ex vivo specimens by recording 5 readings per 
nodule with five repetitive readings per each site. Final pathology reports were used to 
confirm the diagnosis. The spectra were analyzed using principal component analysis, 
linear discriminant analysis and leave one out technique. The in vivo ESS study was 
conceptually designed and IRB approval from Boston Medical Campus was obtained.  
Results: The ex vivo study showed that ESS could predict the difference between benign 
and malignant tumors with a sensitivity of 74%, specificity of 90%, positive predictive 
value of 82% and negative predictive value of 85%. 193 spectra were analyzed from 64 
patients, 120 spectra were from benign nodules and 73 from malignant nodules. Sub-
analysis examined only indeterminate nodules showed sensitivity of 65%, specificity of 
79%, PPV 77% and NPV 67%. The in vivo ESS probe was designed and 12 identical 
instruments were manufactured. Initial experimental readings were taken and parameters 
were adjusted for the in vivo tissue environment. The clinical trial is underway.  
Conclusions: ESS is a practical tool that can accurately identify malignancy in ex vivo   
thyroid specimens with high specificity and sensitivity. Initial in vivo experimental trials 
have been conducted and show promise for similar results.  
vii 
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INTRODUCTION 
The Thyroid Gland  
The thyroid gland is a bi-lobed organ located anterior to the trachea in the neck. An 
isthmus connects the two lobes, with each lobe measuring about 3-4 cm long and 2 cm 
wide.1 The gland normally weighs 25 grams and can be palpated during a physical exam. 
A fibrous capsule covers the gland, and four parathyroid glands are embedded in the 
thyroid. The thyroid gland is also located very close to the recurrent laryngeal nerves, 
which become clinically important in surgery, as they must be identified and preserved to 
prevent damage to the patient’s voice. On a histological level, the thyroid gland is 
composed of many follicles, each of which has a central colloid surrounded by follicular 
epithelial cells and parafollicular cells. The colloid is filled with thyroglobulin, a storage 
protein and precursor for the thyroid hormones (TH): thyroxine (T4) and triiodothyronine 
(T3). The follicular cells produce thyroglobulin and secrete T3/T4 hormone while the 
parafollicular cells produce calcitonin, a hormone that regulates plasma calcium levels. 
The function of the thyroid gland is synthesis, storage and secretion of TH, which 
is involved in either amplification or diminution of physiological processes. TH has 
multiple organ targets and acts primarily to increase metabolism and cell activity. TH 
also has a significant effect on both fetal and juvenile growth and development. TH is 
synthesized using the amino acid tyrosine in the thyroid gland in response to thyroid 
stimulating hormone (TSH) released from the anterior pituitary gland, which in turn is 
released in response to thyrotropin releasing hormone (TRH) from the hypothalamus. 
Tyrosine must be iodinated for synthesis to occur and iodine is obtained from circulation. 
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Iodine deficiency can lead to thyroid abnormalities and is correlated with a higher chance 
of developing thyroid nodules.2 
 TH is necessary for normal growth and development and also controls the rate of 
metabolism. TH essentially affects every organ in the body. In bone, TH activates 
osteoclasts and osteoblasts to perpetuate the bone remodeling process that occurs 
throughout life. Excess levels of TH in adults can result in a higher chance of 
osteoporosis. In the brain, TH has roles in expressing genes involved in myelination, cell 
differentiation, migration, signaling and is necessary for axon growth. In the liver, TH 
regulates the metabolism of cholesterol, triglycerides and maintains lipoprotein 
homeostasis. In the cardiovascular system, TH increases cardiac output and blood volume 
while decreasing systemic resistance in the blood vessels. In fat, TH stimulates various 
white adipose tissue differentiation and proliferation.  
Hyperthyroid, hypothyroid and euthyroid correspond to high, low and normal 
levels of TH function, respectively. Abnormalities in thyroid function can be genetic or 
acquired and the duration of the abnormalities can be permanent or temporary. Thyroid 
dysfunction is more common in females, primarily due to the higher incidence of 
autoimmune disorders in women. Abnormalities include benign or malignant goiters 
(thyroid gland enlargement), autoimmune disorders such as Graves’ disease, Hashimoto’s 
thyroiditis and post-partum thyroiditis. Hyperthyroidism is treated using drugs that 
decrease overproduction of TH (thioureas), drugs that inhibit TH synthesis (adrenergic 
blocking agents), surgery, and radioactive iodine therapy (destroys part of thyroid tissues 
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when administered in sufficient amounts). Hypothyroidism is treated with hormone 
replacement therapy (HRT), primarily with varying dosages of levothyroxine.   
 
Thyroid Cancer 
Thyroid cancer is the most common endocrine disorder. In 2010 alone, about 44, 
670 new cases of thyroid cancer were 
diagnosed with three quarters of them being 
female3. Furthermore, there has been an 
increase in the incidence of differentiated 
thyroid cancer since 1980 across gender and 
race.4 Thyroid cancer is the 7th most 
common malignancy in women.5 The 
increase in diagnosis of thyroid cancer is primarily due to incidence of papillary thyroid 
cancer (PTC). Initially, the increase in thyroid cancer was attributed to better diagnostic 
techniques but the overall trend points to an increase in thyroid cancer in general. 
Thyroid cancer is the growth of cancerous cells in the thyroid gland. A thyroid tumor 
develops when the growth of a single thyroid epithelial cell evades the normal 
mechanisms regulating cell division and gains a selective growth advantage, proliferating 
uncontrollably.5 If this growth continues, a clinically identifiable tumor mass will be 
present. Such unregulated cell division can arise from mutations in oncogenes and tumor 
suppressor genes.5 Thyroid cancer occurs in various age groups but is more prevalent 
among those older than 30.6 There are four types of thyroid cancers, some more common 
Figure 1: Histology of Papillary Thyroid 
Cancer2 
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than others. Papillary or mixed papillary/follicular cancer is the most common followed 
by follicular/Hurthle cell cancer, medullary cancer and anaplastic cancer.6 PTC, follicular 
thyroid cancer (FTC) and anaplastic thyroid cancer (ATC) are derived from thyroid 
follicular epithelial cells. Typical histology of PTC is shown in Figure 1. Both PTC and 
FTC are considered differentiated cancers while ATC is thought to arise from 
differentiated cancers. About 70-75% of PTC cases are associated with risk factors such 
as radiation exposure in childhood and family history of thyroid cancer.7-9 Most PTC 
patients don’t actually die of the disease and mortality in patients without metastases is 
about 6%.9-10 Treatment options for thyroid cancer include: surgery (total or partial 
thyroidectomy), radioiodine therapy, thyroid hormone suppression and the rarely used 
external beam radiotherapy. Other diseases of the thyroid organ include medullary 
thyroid cancer (MTC), primary thyroid lymphoma or metastases from the breast, colon, 
renal cancer or melanoma.11  
The identification of a palpable nodule and the subsequent clinical management is 
one of the first steps in identifying thyroid 
carcinoma (see Fig 2). About 5-10% of the 
general population have thyroid nodules but 
only 5% of these people harbor a malignancy.12 
A nodule is an abnormal growth of tissue that 
can be benign or malignant. Benign nodules are 
classified as adenomas (follicular, microfollicular, and Hurthle cell neoplasms), colloid 
nodules or chronic lymphocytic thyroiditis (Hashimoto’s).2 A thyroid with many nodules 
Figure 2: Thyroid Gland with Nodule2 
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is classified as a multinodular goiter. The cause of thyroid nodules is not known but has 
been found to be associated with iodine deficiency, radiation and TSH abnormalities.13 
Nodules are discovered either by palpation during a physical exam or ultrasound.14 
Cancers are found in 10-14% of patients with palpable thyroid nodules with PTC being 
the most prevalent.13 Guidelines recommend that nodules greater that 1 cm should be 
evaluated.17 Thyroid function tests give little insight on the condition of the thyroid as 
abnormal blood TH levels don’t confirm malignancy. Once a nodule is identified, a 
biopsy is performed to discover if the nodule harbors a malignancy. Most thyroid cancers 
are curable, especially if they are identified at a young age. The American Thyroid 
Association (ATA) along with most endocrinologists and endocrine surgeons, 
recommend a near total or total thyroidectomy for patients with well-differentiated 
thyroid cancer.15-16 The use of 131I as a post surgical treatment favors a total 
thyroidectomy and is correlated with an improved overall survival rate and lower 
recurrence rates.17  
  
Current Diagnostic Techniques  
Historically, thyroid scanning with radioiodine was used to differentiate between 
benign, hot nodules and further evaluation was used for cold lesions (non-function 
nodules).2 This approach had disadvantages including avoidable exposure to radiation 
and inability to distinguish between benign and malignant cold nodules. Thyroid 
scanning was replaced by fine-needle aspiration biopsy (FNA) as the primary diagnostic 
technique in the thyroid. The FNA is considered the preferred approach because the 
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technique has been perfected and cytology interpretation has significantly improved since 
its first use. Advantages are: a quick, minimally invasive procedure that provides 
valuable pathology results regarding the condition of a thyroid nodule.2 Before a FNA is 
performed, hypo- and hyperthyroidism must be ruled out which are both easily identified 
by measuring TSH levels.2 FNA is a biopsy method that uses a needle to extract a small 
amount of thyroid tissue to be examined by pathologists.6 Local anesthetics are not 
frequently used because they cause another lump over the one that must be biopsied.2  
 The nodule is identified by palpation or ultrasound (US) and the needle is inserted 
into the center of the lump perpendicular to the skin and suction is applied in a gradual 
manner (Figure 3). Tissue is obtained using 23 to 27 gauge needles with ultrasound 
guidance.18 If there is blood in the syringe, the procedure is halted and the needle must be 
re-inserted. The number of passes or aspirations depends on the size of the nodule; for 
example, 3 aspirations are taken for nodules larger than 3 cm.2  FNA pathology results 
Figure 3: Fine Needle Aspiration Biopsy2 
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allow for accurate diagnosis of which type of thyroid malignancy is present in the cells. 
Cytopathologists report whether their findings are diagnostic or non-diagnostic. Non-
diagnostic aspirates have insufficient cells or cells of indeterminate nature while 
diagnostic findings are classified as malignant, benign or suspicious for malignancy (see 
Figure 4 below). The ATA guidelines for cytological categories are: non-diagnostic (10-
15%), benign (60-70%), malignant (5-10%), and indeterminate (10-25%)17. Thyroids 
with malignant and suspicious lesions are recommended for thyroidectomies.  Patients 
with a malignant nodule greater than 1 cm should undergo thyroidecotmies according to 
ATA guidelines.19-20 Patients with benign cytology may undergo surgery for symptoms 
Figure 4: Clinical Management of A Thyroid Nodule 
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such as tracheal compression or obstruction, trouble swallowing, and apnea. Otherwise, 
patients with benign cytology are followed up in clinic with ultrasonography or physical 
examination.  
Other diagnostic techniques, such as thyroid scanning with radioiodine, that are 
less invasive are also used but the FNA is the only approach that can distinguish between 
benign and malignant tumors.2 While FNA is the standard technique used to biopsy 
thyroid nodules, it is not 100% accurate and patients often undergo un-necessary surgery 
due to indeterminate FNA results. Patients with non-diagnostic FNA results frequently 
undergo surgery for definitive diagnostic purposes. The FNA technique requires both the 
expertise of the physician performing the FNA itself and an expert cytologist to interpret 
the results.2 Figure 4 demonstrates clinical management after FNA results.  
Overall, around 5-10% of nodules tend to be malignant, but about 10-25% of 
diagnoses based on FNA 
results are inconclusive12. 
Of those classified under 
“indeterminate” cytology, 
most end up benign. Such 
inconclusive results cause 
twice as many 
thyroidectomies done on patients with benign nodules than malignant nodules.12 Figure 5 
shows the correlation of diagnoses based on FNA versus histological techniques. Of 
those inconclusive results, a repeat FNA is usually performed to see if another aspiration 
Figure 5: Correlation between FNA and histological diagnosis2 
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results in determinate cytology. FNA has been found to have a range of unsatisfactory 
results varying from 5% to 43.1%.2 Such a large range warrants a need to discover and 
develop more accurate diagnostic techniques.  
The current objective of thyroid cancer research is to improve the prediction of 
benign from malignant tumors based on molecular techniques such as increased or 
decreased gene expression. Efforts have been made to identify molecular markers that 
could possibly distinguish the difference between malignant and benign nodules. A few 
of these markers include galectin-3, cytokeratin, BRAF, and PAX8-PPARg.17 Some these 
genetic markers have shown accuracy in diagnosis such as BRAF, Ras and RET-PTC and 
protein marker galcetin-3.17 Furthermore, both mRNA and microRNAs have been studied 
to develop gene models that will be able to predict the benign or malignant state of a 
thyroid nodule.17 Research that focuses on improving diagnosis of malignant versus 
benign nodules has focused on differences in up-regulation or down-regulation of 
specific miRNAs.12 Unfortunately, the gene assays have not been implemented and 
applied in clinical settings and have shown to have significant reliability in only a few 
selected laboratories. Another test involving 18FDG-PET scanning has been shown to 
have high sensitivity for malignancy but low specificity and again has shown varied 
results among different studies.21 The thyroid clinical “conundrum”, the high incidence of 
patients with benign thyroids that under thyroidectomy surgeries for diagnostic purposes 
and consequently live with hormone replacement therapy (HRT) for the remainder of 
their lives, must be addressed. It is evident that more accurate non-invasive diagnostic 
techniques could significantly reduce the number of un-necessary surgeries. Ideally, this 
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diagnostic tool should both be cost effective and applicable in clinic for widespread use. 
If such a diagnostic tool was found and applied in clinic, it could reduce both healthcare 
costs and the number of patients with benign thyroid nodules from undergoing both 
surgery and HRT.  
 
Optical Spectroscopy as a Diagnostic Tool in the Thyroid  
Optical spectroscopy has been studied in its capabilities of diagnosing malignancy 
in a variety of conditions. Optical spectroscopy implements techniques that detect a 
change in the property of light when it interacts with tissue and this change is used as a 
diagnostic measure.22 Optical tissue diagnosis involves the emission and collection of 
light via fiber optic probes to perform minimally invasive real time assessment of tissue 
pathology in situ. Some optical biopsy methods include Raman spectroscopy, 
fluorescence spectroscopy, optical coherence tomography and elastic scattering 
spectroscopy (ESS). Each technique manipulates a different aspect of optical 
spectroscopy and uses the variation among recordings as a way to analyze the 
pathological state of tissue. Tissues that harbor malignancies generally undergo changes 
at the molecular and cellular level and these changes are reflected in optical spectroscopy 
recordings. Advantages of optical spectroscopy diagnosis are virtually the same; 
reduction of inter or intra-observer bias in pathological diagnosis, real time application, 
virtually immediate diagnosis, decreased patient anxiety in waiting for results, and its 
minimally invasive application.12, 22  
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Raman spectroscopy takes advantage of the inelastic scattering of monochromatic 
light that is emitted from a laser in various light spectrum regions (from infrared to 
ultraviolet). The emitted light then interacts with molecular vibrations causing a change 
in the excitation state of the photons. The recording of the change in the excitation state is 
used to diagnosis different pathological states. For example, Raman spectroscopy has 
been found to be helpful in detection of molecular changes between a thyroid goiter and 
PTC.23  
Fluorescence spectroscopy manipulates the fact that all tissues have flurophores 
and thus absorb and re-emit light in the form of fluorescence. The amino acid tryptophan, 
NADH and collagen are examples of fluorophores.24 As tissue progresses from normal to 
neoplastic, the number and quality of the fluorphores change and as a result so do the 
fluorescent properties of the tissue. Fluorescence spectroscopy utilizes this change in 
fluorescence as a way to diagnose tissue states. For example, a fluorescence 
spectrophotometer scanned fresh ex vivo thyroid tissue and showed that thyroid tissue 
with different histology reflected varying levels of fluorescence.24 A diagnostic algorithm 
was created based on the results and used for future studies. Fluorescence spectroscopy 
has also been studied in breast, colon, cervical, esophageal, and digestive tissue.24  
Optical coherence tomography is a technique that uses the optical properties of 
tissue to produce a high resolution imaging of the tissue morphology. A portable imaging 
system uses a laser light source to produce 3D optical images that cover a volume of 
3x1.5x1.3 mm3.25 Optical coherence microscopy can produce images with resolution 
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lower than 10 microns.25 In thyroid tissue, optical coherence microscopy has been used to 
assess the difference between ex vivo benign and malignant tissue.  
While the above optical spectroscopy techniques have show promising results in 
the thyroid, many have limitations. Proper diagnosis of thyroid pathology based on 
Raman spectroscopy varies from 58.3-72.5%, which does not demonstrate better 
predictability than FNA.23 Fluorescence spectroscopy, similarly, did not have sensitivity 
and specificity findings higher than FNA and shows more promise as a localization aid 
rather than a diagnositic tool.24 Optical coherence tomography, while providing extensive 
information about the thyroid condition at the microscopic level, is not currently suited 
for in vivo use due to long imaging speeds.25 Unlike the other optical spectroscopy 
techniques, ESS has shown promising results both in thyroid and other tissue with 
significant specificity and sensitivity as well as practical clinical application.   
 
Elastic-Light Scattering Spectroscopy (ESS)  
 Another more novel approach involves the use of elastic light scattering 
spectroscopy (ESS) to diagnose the 
difference between malignant and 
benign thyroid nodules.  ESS is a point 
spectroscopic measurement based on 
sub-cellular morphology and the cellular 
composition of tissue. ESS operates 
under a large wavelength ranging from 
Figure 6: Example of Light Scattering from ESS 
probe 
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320 nm to 900 nm in the current system.17 The key to ESS is that it senses the size and 
structures of sub-cellular components that change due to tissue transformation. When a 
normal cell becomes a cancerous cell, there are cellular and sub cellular changes that 
occur. These transformations include changes in size and hyperchromaticity of cell 
nuclei, chromatin granularity, nuclear crowding, size/density of the mitochondria and 
other cell organelles, nuclear/cytoplasm ratio and refraction indices of particles.17, 26, 27  
 ESS is conceptually based on the Mie theory, which states that when light hits a 
particle, there will be forward, side and back elastic light scattering that is relative to the 
size of the particle.28 Photons scatter elastically from cells due to gradients and 
discontinuities in the refractive index. Scattering 
differs from absorption in that absorption is due to 
the presence of a variety of chromophores, 
compounds and fluids that constitute tissue while 
scattering is a result of gradients and 
discontinuities in the refractive index.28 The Mie 
theory (which is based on spherical particles) is 
applied to cells even though all components within the cell are not spherical because they 
still retain the qualitative features of the model.27 According to the theory, the smaller the 
particle, the less light it absorbs. The coated sphere model, an application of the Mie 
theory, is most commonly applied to describe the cell in terms of elastic scattering. The 
cell is thought to have two separate components, the scattering center and the surrounding 
cytoplasm. The scatterers are considered to be homogenous spheres and the probability of 
Figure 7: Example of movement of 
light after interacting with organelles 
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scattering is dependent on the size parameter. The amount of scattering from a spherical 
particle illuminated by a plane wave is dependent on the diameter of the scatterer, index 
surrounding the medium, the illuminating wavelength and the scattering angle.27 By 
using ESS to measure the angle and/or wavelength dependence of scattering probability 
of cells, inferences about the size and density of structures causing scattering can be 
made. The differences in morphology of apoptotic and normal cells in the thyroid 
produce detectable differences in ESS spectra.27 The amount of directly and indirectly 
back scattered light measured by ESS creates a unique spectral signature for benign and 
malignant thyroids, respectively. The ESS spectra are created by the wavelength 
dependent on optical scattering efficiency and the effects of changes in the scattering 
phase function, which are caused by optical index gradients.17  
ESS generates spectral signatures based on changes that occur in various thyroid 
pathologies, which can be used as a diagnostic tool. The changes in nuclear size, density, 
chromatic granularity, mitochondrial size produces different spectral signatures, which 
serve as the optical spectroscopy equivalent to histological changes in the same tissues.17  
Suh et al found that ESS spectra collected from fresh ex vivo thyroid specimens was able 
to predict benign versus malignant thyroids with significant sensitivity and specificity.17 
One of the first studies of its kind, it serves as preliminary data for future in vivo studies 
using the ESS optical probe technique.  
Use of ESS spectra as a diagnostic technique or adjunct FNA has multiple 
advantages. ESS allows for immediate diagnosis, has higher sensitivity compared to 
FNA, decreases patient anxiety due to less waiting time for a diagnosis, reduces 
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healthcare cost29, does not require expert interpretation, is a form of empirical analysis, 
does not perturb the cellular environment or alter it, is sensitive to changes as early as 
possible, and is a mobile and light weight unit. As ex vivo results have been promising, 
the next logical step has been to design an in vivo model of the thyroid ESS probe and 
test it. One disadvantage of ESS in the ex vivo study was that it was necessary to have 
freshly sectioned tissue to conduct the study.17 Similar findings have been reported in 
diagnostic studies such as in Barrett’s esophagus30-33, colonic polyps,34 oral cavity lesions 
35, 36, lymph nodes37 and bone35, and breast cancer.38-40  
 
Design, Concept and Challenges of an in vivo trial using ESS Optical Probe  
The process of designing an optical probe that can be used in vivo proved to be 
challenging. Many factors had to be taken into account beginning from the actual 
materials used to construct the probe to the work flow in both the operating room and 
clinic. While no in vivo ESS tools have been studied in the thyroid, there have been 
promising data using in vivo ESS technology in a variety of organs such as brain tissue, 
esophagus, cervix, colon, melanoma, atherosclerosis, ocular tissue, diabetes mellitus, and 
the metabolic state of cornea26. With the supporting results of previous ex vivo studies 
and in vivo ESS experiments conducted on other organs, designing an experimental in 
vivo ESS probe for the thyroid gland is the next goal.  
The first steps involved designing and manufacturing the probe. The box was 
designed to be identical to the ex vivo ESS box with a xenon lamp, spectrophotometer, 
and computer. The box would have to be easily transported and not carry substantial 
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weight as probing will take place in various locations such as the operating room, frozen 
section room, pathology department, and the endocrine clinic. Xenon light was chosen as 
the light source for both ex vivo and in vivo data collection because it provides the most 
continuous broad whitest band length in comparison to other noble gases. Xenon has a 
continuous spectrum covering the ultraviolet (UV) to infrared (IR) light regions (200 nm-
1100nm).  Additionally, the xenon lamps have a small arc size, which makes it easy to 
couple to fiber optics and provide high radiant power when used in pulse mode.28 The 
connector would go from in and out of the probe to the xenon box. The probe itself fits 
inside a 23-gauge needle and can be retracted or deployed as needed. The source fiber 
measures 150 mm while the collection fiber measures 100 mm. The ability to move the 
probe in and out of the needle is necessary to allow for multiple passes and switching to 
the biopsy syringe for tissue collection. The probe itself extends only 0.5 mm beyond the 
tip of the needle. It was necessary to decide whether the probe instrument would be re-
usable or disposable and choose a cleaning and sterilization process. Also, as FNA biopsy 
is frequently paired with ultrasound guidance, operating the whole system with one hand 
or a foot pedal to trigger recordings would be ideal and more user-friendly. Lastly, the 
calibrator is a SpectrolonTM, which allows for a reference spectrum to be set at a fixed 
distance. The SpectralonTM is fluoropolymer, a material known to have the highest 
diffuse reflectance over the UV to IR spectrum.28 Use of the SpectralonTM as a calibrator 
allows for the setting of a reference spectrum that reflects nearly all the xenon light 
emitted. The calibrator will be kept sterile.  
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After initial design of the probe, Institutional Review Board (IRB) approval was 
obtained, which usually takes approximately 6 months. The personnel using the 
technology need to have Office of Human Subjects Research (OHSR) certification 
understand the technology as well as the importance of conducting these clinical trials. 
OHSR is a division of the National Institute of Health (NIH) that provides a tutorial on 
laws and ethics of conducting research on human subjects. An assessment must be passed 
to receive OHSR certification from NIH.   Unlike the ex vivo studies, the surgeon will 
have to introduce the trial and obtain consent from patients due to increased trust issues 
as the trial will be conducted in vivo . As a result, the patients will have to be thoroughly 
educated about the trial, as well as about its risks and benefits. Some of the risks include 
bleeding, infection and possible electrical mishaps in addition to those risks patients 
undertake by agreeing to undergo a thyroidectomy or FNA biopsy. The benefits are 
limited to the actual patients themselves but are many for society. If the in vivo ESS 
probe proves to have significant diagnostic capabilities, its use in adjunction to FNA 
could significantly reduce the number of diagnostic surgeries. The sample size is difficult 
to predict as such a study has never been done before but with such high enrollment 
numbers for the ex vivo trials, recruitment of a significant number of subjects seems 
feasible. Conducting the trial in the operating room (OR) will be easy to implement as the 
thyroid is already scheduled for removal. Using the data obtained in the OR will give us 
pertinent information about how perfusion affects spectral readings. In clinic portion of 
the study, the probe will be used in adjunct to the FNA and as a diagnostic tool in the 
future.   
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The Food and Drug Administration (FDA) has given the in vivo probe a no 
significant risk (NSR) to the patient designation because it is deployed through the FNA 
needle and emits harmless light that does not cause heat or changes in the tissue. By the 
FDA’s definition, a medical device is a tool that is “intended for the use of diagnosis of 
disease or other conditions, or in the cure, mitigations, treatment or prevention of disease, 
in man or other animals”.41 Currently, the probe is categorized as an experimental device 
and no brochure exists because it is not a commercial device, is completely noninvasive 
on its own as it deploys through the already approved FNA needle and does not alter or 
remove tissue. The in vivo ESS probe is considered an in vitro diagnostic product (IVD) 
as it is an instrument used in the diagnosis of disease or other conditions and its data 
collection is taken from the human body.41-42 IVD products are classified into classes of 
regulatory control to ensure their safety and effectiveness in the market. The 
classification of the medical device determines the process it will undergo prior to 
introduction into the market. This will be done after results from the current study are 
determined. The Center for Devices and Radiological Healthcare (CDRH), a part of the 
FDA, is responsible for approving and regulating medical devices for marketing. The 
current clinical trial using the in vivo ESS probe will focus on safety while future clinical 
trials will focus on large-scale significance and ability to implement the medical device in 
multiple institutions.  
The use of the in vivo optical probe at the patient bedside posed some challenges. 
While the use of a re-usable probe for the preliminary studies serves the purpose of 
collecting data on its diagnostic ability, applying the probe on a larger scale in this 
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manner would be time consuming and impractical.  For the preliminary in vivo studies, 
twelve re-usable probes were constructed and will be distributed for use between the 
endocrine clinic and two sets of operating rooms at Boston Medical Center (BMC). The 
CPD (Central Processing Department) and researchers reviewed the different sterilization 
techniques and processing procedures of the instruments that could be used.  The probe 
that will be used commercially will need to have an integrated optical probe biopsy 
needle packaged and already sterilized. The probe itself may be sterilized using an 
autoclave or ethylene oxide sterilization (EtO) process. Due to the high temperature 
required for autoclave sterilization, EtO will be used as a disinfectant to replace the high 
temperature steam. This allows for the use of plastic components in the probe. Similarly, 
as the probe will be used in the OR and clinic, multiple boxes will need to be stored in 
these locations to provide easy access and data collection during normal medical 
procedures. The individuals conducting the actual FNA diagnosis will need to be trained 
in how to use the in vivo ESS probe or a research assistant will need to be present to 
monitor the process and data collection. In the endocrine clinic, use of the in vivo ESS 
probe will not pose an inconvenience as the endocrinologist is already doing an 
ultrasound guided FNA and inserting a biopsy needle into the patient’s thyroid. However, 
in the operating room the use of ultrasound is not typically utilized. The solution to this 
dilemma is to either do ultrasound without radiology, which will not be compensated and 
will require training, or to only include palpable/larger lesions in the OR component of 
the study.  Post ESS data collection, the probe will need to be cleaned and sterilized for 
future use. Data will be compiled on the computer and stored for retrieval for future 
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analysis. After data has been compiled, a new algorithm will be created that demonstrates 
which morphology changes are most indicative of malignancy specifically in the thyroid 
gland. This algorithm will then be used for future studies and continue to be updated as 
new data is added to help determine whether a nodule is benign or malignant based on 
ESS spectral data. Quality assurance will be assessed by both patients and researchers 
and changes will be made if necessary.  The final outcome of the in vivo ESS probe 
clinical trial is to assess whether the in vivo probe is as good as or better than the ex vivo 
probe in predicting malignancy in the thyroid gland. 
 
Specific Aims or Objectives 
While FNA is the current accepted diagnostic procedure for determining 
malignancy in the thyroid, it is not 100% accurate or foolproof. The development of an 
optical probe that uses ESS could possibly minimize FNA shortcomings by providing 
more accurate diagnosis of malignant nodules. Combining other diagnostic technology 
with the FNA will increase its accuracy and as a result decrease the number of surgeries 
done solely for diagnostic purposes. The aims of this research is to gather a significant 
amount of data with a higher sample size than previous ex vivo studies and to design and 
produce the in vivo ESS probe for use and initial clinical trials. The purpose of 
developing this technology is aimed at improving diagnosis during biopsy, avoiding 
surgery for solely diagnostic purpose and improving medical knowledge. As a result, this 
research will provide significant benefit to society and new insight about thyroid cancer 
diagnosis.  
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MATERIALS AND METHODS 
Ex vivo Study using ESS 
ESS equipment:  
 
 
The Elastic Scattering Spectroscopy (ESS) system is comprised of a pulsed xenon 
arc lamp, an optical probe fiber, a spectrometer, and a computer that controls the various 
components and records the data. ESS involves directing short pulses (~1 ms) of white 
light (~320-920 nm) from the xenon lamp (made by Perkin Elmer, Incorporated) through 
the flexible emission optical fiber that is put in contact with the tissue to be examined. 
Ultraviolet B (280-315 nm) and ultraviolet C (100-280 nm) light are filtered out to avoid 
any potential risks to patients and the tissue. There is a collection fiber, approximately 
Figure 8: ESS computer and fiber probes 
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200 µm in diameter, that is fixed at a distance of 350 µm (center to center) from the 
emission fiber that records the back scattered light from the upper layers of the tissue and 
sends it to the spectrometer (S2000 Ocean Optics). The complete fiber assembly 
measures 1.5 mm in diameter and the distal end is housed in a rigid stainless steel casing 
for easy handling and sterilization while collecting probe data. The spectrometer that 
displays the recorded spectrum on the computer, records it for use in further analyses. 
The spectrum shows the different intensity levels of back scattered light at various 
wavelengths. The collection and recording of a single spectrum takes less than 0.25 
seconds with the integration time of the detector being the limiting factor (~20-40 ns per 
pulse). Figure 8 shows a diagram of the complete ESS system.  
 
System calibration: 
First, a white light reference spectrum is recorded before any ESS spectra measurements 
on ex vivo tissue are taken. The reference spectrum establishes the system response by 
recording the diffuse reflectance from a flat surface of Spectralon TM (Labsphere, 
Incorporated), which is flat between 250 and 1000 nm. Setting the reference spectrum 
based on a SpectralonTM allows for variation in spectra due to light source, spectrometer, 
fiber transmission, and fiber coupling to be identified when analyzing data. To produce a 
system independent spectrum for investigation, every consequent spectrum recorded is 
divided by the reference spectrum.  
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Patient Selection and ex vivo Measurement Procedure: 
The study was approved by the Institutional Review Board (IRB) of Boston Medical 
Center (BMC) and informed consent was obtained from patients with thyroid lesions 
already undergoing thyroidectomies. Prior to participation, patients were consented for 
both optical probe and miRNA studies. Since summer of 2009, 227 patients undergoing 
thyroidectomies at BMC were assessed and 91 were excluded from the study due to 
changes in OR schedule, tissue fixation by formalin, incidental carcinomas or carcinomas 
measuring less than 1 cm. 136 patients were consented and enrolled into the study. Figure 
9 shows the enrollments and outcomes of patients. ESS data was collected from ex vivo 
thyroid specimens in the pathology department within 30 minutes of surgical removal and 
prior to formalin fixation. A pathologist dissected and sectioned the thyroid specimen on 
site, and ESS readings were taken on preoperative FNA examined nodules and/or the 
most prominent and suspicious nodules. Readings were also performed on available 
adjacent normal tissue, if possible. All nodules were bivalved, and spectra were obtained 
from five sites with five repetitive readings per site per nodule on average, depending on 
the size. At measurement time, the fiber probe was calibrated and the tip of the probe was 
placed in contact with tissue site of interest and measurement was activated at the 
keyboard of the attached computer. The system automatically takes a background 
measurement without firing the lamp, followed within 100 ms by an ESS measurement 
with the pulsed lamp being triggered and then subtracts the background spectrum from 
the ESS spectrum. The entire process was controlled by the computer which allowed for 
both accurate and reproducible measurements as well as providing a graphical display of 
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the spectrum. The whole data acquisition and display time takes less than 1 second for 
each measurement site. 
   
Spectral Acquisition: 
The spectra were collected in manner in which to reduce the number of planes from the 
greatest exposed diameter of the nodule. Hemorrhagic, necrotic and degenerative cystic 
tissue was avoided. The ESS data samples were co-registered with their respective pre-
operative FNA biopsy results (when available) and final histopathology results along 
with collected tissue samples of both nodular and normal tissue.  
Figure 9: Enrollment and Outcome Flow Chart for ex vivo study 
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Histopathology: 
After spectra and tissue samples were collected, thyroid specimens were fixated in 
formalin and sent for histopathological processing. The final surgical histopathology 
diagnosis, conducted by an independent pathologist at the Boston University Department 
of Pathology, was used as a gold standard. After obtaining these results, the spectral 
readings were classified as normal, benign nodule, or malignant. In prior studies, normal 
tissue was easily distinguishable from benign and malignant nodule so it was excluded in 
further analysis.  
 
Patients inclusion/exclusion analysis criteria: 
Of 136 patients enrolled in the study, all were chosen based on their final surgical 
histopathology diagnoses. To maintain a high consistency in co-registration of ESS data 
with histopathology diagnoses, patients with microcarcinomas (<1cm), chronic 
lymphocytic infiltration (thyroiditis), Graves’ disease, Hashimoto’s disease and muti-
focal nodules were excluded from analysis.  
Figure 10: Fresh ex vivo thyroid specimen and example of data collection using ESS probe 
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Spectral Processing and analysis:  
All spectra used in analysis underwent smoothing, a process in which each intensity point 
is replaced by the average of the 20 neighboring intensity points. Then, the smoothed data 
was reduced from original 1801 points to 180 intensity values to speed up further 
manipulation. The wavelength window was reduced from 320-920 nm to 340-900 nm to 
remove regions of the spectra that had low signal to noise ratios (which come from the 
lower light intensity emitted by the xenon arc lamp at the extremes of its output 
spectrum). To standardize the smoothed spectrums, the mean intensity of the spectrum 
(average intensity over entire spectral range) was subtracted from each data point. Then 
each point was divided by the standard deviation of the smoothed spectrum. This 
standardization method gave all the spectra a mean intensity of zero and a standard 
deviation equal to one. The method allowed for the emphasis of the relative intensities 
across the whole wavelength rather than the actual light intensity, and as such the number 
of light pulses used to generate a spectrum did not have to be taken into account when 
analyzing the spectra.  
 In the spectra used, no obvious outliers were detected but a number of 
unstandardized spectra were negatively saturated (had an intensity of zero). These 
negatively saturated spectra were found at 420 and 550 nm and corresponded to 
hemoglobin absorption peaks. In all the cases, the spectra were saturated only at the 
center of the peaks and not anywhere else. The saturation was thought to have a minimal 
effect on the rest of the spectrum so it was not removed from the analysis. 
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 Principal component analysis (PCA) was used to reduce the data to only regions 
that demonstrated large variability using Systat, a statistical package. Next, linear 
discriminant analysis (LDA) was then performed (also using Systat) on the principal 
components to improve on the discrimination between benign and malignant nodules. 
The “leave one out” method was used for cross validation. A single data point is used as 
the validation data while the rest of the points are used as the training data. ESS data from 
one of the samples of the 136 was left out for analysis and classified based on known 
final histopathology and ESS readings of the other samples. This helped determine how 
accurately a learning algorithm is able to predict data it has not been trained on. 
Sensitivity and specificity were defined where sensitivity = SE = TP/(TP + FN) and 
specificity = SP = TN/(TN+FP), where TP = true positive, FP = false positive, TN = true 
negative, and FN = false negative. Positive predictive value (PPV) and negative 
predictive value (NPV) were defined where PPV = TP/(TP + FP) and NPV = 
TN/(TN+FN). 
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In vivo Study using ESS 
Figure 11: In Vivo ESS probe instrument 
 
 
ESS instrument:  
The in vivo optical probe system is comprised of a portable spectrometer unit that utilizes 
ESS and has been previously used in ex vivo and in vivo clinical studies at various 
medical centers and BMC. Light is directed at a broad range of wavelengths (320 nm-800 
nm) from a pulsed xenon lamp (Perkin Elmer) onto the tissue of interest through a 
flexible optic fiber measuring 150 mm. A second fiber, located near the first and 
measuring 100 mm, records the light scattered from the nearest layers of tissue and 
examines it with a spectrometer (S2000 Ocean Optics). The whole fiber is 2 mm in 
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diameter and the distal end fits through the bore of a standard 23-gauge FNA needle 
(currently needle size used for FNA at BMC). The distal end is housed in stainless steel 
tubing to allow for sterilization and easy cleaning.   
 
Design:  
 Subjects will be recruited from the Surgical Oncology Practice and the Thyroid 
Clinic at Boston University School of Medicine (BUSM),  in BMC under the direction of 
Dr. Jennifer Rosen and Dr. Stephanie Lee respectively. Patients undergoing a standard 
FNA of their thyroid gland as a part of their normal clinical care will be eligible for the 
study. They will undergo their normal procedure and the specimen will be sent to 
pathology for diagnosis. Readings using the optical probe will be obtained at the same 
time as the biopsy. For the pilot study with feasibility trial, 300 patients will be included 
initially. The sample size was chosen to complete the study in one year and test the 
hypothesis that optical spectroscopy can differentiate between normal thyroid, benign 
thyroid, thyroid cancer and parathyroid tissue. Each patient’s specimen will serve as its 
own control because the biopsy needle passes through normal thyroid en route to the 
thyroid nodule. The IRB at Boston Medical Center approved the study.  
 
Subject Inclusion Criteria: 
 Subjects will be of both genders, ranging from ages 18-64 years old, of all ethnic 
groups and will speak English. No children will be included in the study. Additionally 
subjects will already be undergoing a thyroid biopsy for thyroid nodules, thyroid cancer 
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and thyroid goiter with nodules. Only patients already undergoing a biopsy for clinical 
purpose will undergo optical biopsy as the same time as their physical biopsy. The 
projected sample size for this study is 300. The initial ex vivo pilot trial had a 99.9% 
enrollment rate of eligible subjects and with over 550 thyroid biopsies performed at 
BUMC every year, the enrollment of 300 patients in 1 year is feasible.  
 
Sterilization: 
 The fiber probe assemblies will be sterilized to the same level of surgical 
equipment using ethylene oxide (EtO). The EtO sterilization process consists of 3 stages. 
The optical probe unit is wrapped in porous covering and inserted into the sterilization 
machine. The first step is pre-conditioning, in which temperature and humidity is 
controlled to allow micro-organism growth. The next stage, sterilization involves the 
release of the EtO, which infiltrates the packaging and product to kill the micro-
organisms that have grown in the previous stage. Specifically the process consists of an 
initial vacuum phase, a leak rate test, first flush, second flush, dynamic environmental 
condition, EtO gas injection, sterilization period under EtO, post dwell vacuum level, first 
wash, second wash and final air admission49. The final stage, the degasser stage is when 
the optical probe undergoes a degassing phase to remove an EtO that was left over under 
a temperature-controlled environment49. The entire EtO sterilization process is done in an 
automated machine.  
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Data Collection in the Clinic: 
 Prior to participation in the study, the endocrinologist or surgeon will obtain 
informed consent from the patient after detailing the treatment plan, risks, benefits, 
alternatives, cost, etc. The portable instrument will be brought into the biopsy room and 
calibrated. The FNA needle will be placed into the neck as per standard protocol with the 
optical probe inside of it. With the help of an assistant, the researcher will obtain the 
optical spectra by triggering the spectrometer, which takes less than three seconds. Then 
the optical probe will be removed from the inner portion of the needle and the standard 
FNA will collect a cytological or pathological specimen. Normal pathological processing 
will occur from this point forward. The measurement will not take any longer than 10 
seconds total. The fixed arrangement of the transmission and detection fibers allows for 
comparison of spectra taken at different times and with different probes but the volume of 
tissue that can be sampled is limited to 500 microns depth at the tip of the probe.   
After pathological diagnosis has been made, the subjects will be de-identified, and 
the optical spectra findings will be correlated with the histological criteria for normal 
thyroid, benign thyroid, parathyroid and thyroid cancer. The spectra will then be 
processed and analyzed using algorithms developed prior to comparison with cytology in 
order to determine the amount of nuclei and cytoplasm present.  The optical spectra 
generated are converted to a series of mathematical gradients and intensities using data 
analysis software.  Analysis will be performed with a statistical computer package using 
LDA or a model based analysis that relates increased scattering at shorter wavelengths to 
differences in melanosomes. The training set will consist of 60% of the data and will be 
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used to create a discriminant algorithm while the remaining data will be used for the 
testing set. The test set will use the algorithm obtained from the training set to 
differentiate between thyroid conditions and will be classified into benign, colloid nodule 
or malignant categories. No extra tissue will be collected as part of this study, patients 
will not be told about the results of their optical biopsy and the results will not have a role 
in their clinical care.   
 
Data collection in the OR: 
 The surgeon will obtain informed consent prior to anesthesia administration. The 
surgeon will detail the treatment plan, risks, benefits, alternatives and costs of 
participation in the study. After sterilization has been completed, the portable device will 
be brought to the operating room and calibrated. The in vivo optical probe will then be 
inserted into the thyroid gland where multiple optical measurements will be taken in 
different sites within the nodule and recorded. After the last optical probe reading, an 
aspiration will be taken for diagnostic comparison purposes and the instrument will be 
cleaned and removed from the OR. The surgeon will then proceed with the 
thyroidectomy as planned.  
  
Data Analysis: 
 Once the discriminant analysis has been applied to the testing set, the sensitivity 
and specificities for discriminating between classification groups will be obtained to 
determine the accuracy of the technique. To compare clinical results with optical results, 
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the discriminant results taken from each lesion will be examined and used to determine a 
per-lesion result. Then the collective diagnosis of the lesion will be obtained by taking 
the worst-case diagnosis from the un-weighted median of all spectral diagnoses. After 
this, the sensitivity and specificity values will be calculated again. To obtain overall 
accuracy and the Kappa value, the frequency of diagnoses will be normalized to simulate 
equally weighted sets and then the representative values of accuracy, the Kappa value and 
standard error estimates will be calculated. The difference in accuracy of the different 
analysis techniques will be tested using a Students t-Test with a significance level of 
p<0.05. A follow up study will be necessary to test the training set based on the 
calculated sensitivity and specificity values. The Kappa statistics are only one of the 
statistical tools we plan to use with the intention of accounting for inter-observer 
variability. In future studies, the procedure will be conducted in multiple institutions 
under the supervision of multiple investigators in which cases Kappa statistic will be 
more significant. 
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RESULTS 
Ex vivo Study Using ESS 
 For the ex vivo study, 227 patients were recruited in total. For statistical analysis, 
spectra from 136 of these subjects were available for use. To create the training 
algorithm, 60% of the data was used while the remaining 40% was used to test the 
algorithm in its accuracy. Subjects were left out of statistical analysis for various reasons 
that would confound the findings such as those found with incidental carcinomas, 
carcinomas measuring less than 1 cm, patients with Graves’ disease, and those with 
specimens that were put in formalin prior to optical probe readings.  
Of the 136 subjects available for use, 193 spectra from 64 patients were used for 
statistical testing. The other spectra were eliminated due to high presence of blood, room 
lighting and calibration problems. The “leave one out” technique was utilized to test how 
accurately ESS predicted thyroid tissue condition. The analysis was completed on a total 
of 193 spectra, 120 spectra from benign thyroid tissue and 93 spectra collected from 
malignant thyroid tissue. ESS detected 108 out of 120 benign nodules and 54 out of 73 
malignant nodules successfully. ESS presented 19 false negatives, predicting a benign 
nodule when it was actually malignant and 12 false positives, predicting a malignant 
nodule when it was actually benign. Based on the algorithm with N of 64, the sensitivity 
and specificity were 74% and 90%, respectively. The positive predictive value (PPV) and 
negative predictive value (NPV) were 82% and 85%, respectively (Table 1). 
 A subclass analysis was completed on 59 spectra from 25 patients that had 
indeterminate FNA cytology results. According to histology, 28 were benign and 31 were 
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malignant. With an N of 25, sensitivity was 65%, specificity was 79%, PPV 77% and 
NPV 67%. ESS identified 18 out of 28 benign nodules correctly and 24 out of 31 
malignant nodules correctly in the subclass analysis.  
 
 
 
 
 
 
 
 
 
108 
 
19 Benign 
12 54 Malignant 
Benign Malignant  
Histopathology diagnosis 
ESS 
test 
Table 1. “Leave-one-out” analysis for ESS data  
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In vivo Study Using ESS 
 The in vivo optical probe was successfully manufactured with 11 other identical 
ones available for re-use. The entire instrument is a lightweight unit with the probe 
located inside a 23-gauge biopsy needle. The probe is deployed and retracted by pushing 
down or lifting up the blue lever, respectively. The source fiber measures at 150 mm 
while the collection fiber measures at 100mm. Subject recruitment is underway in both 
the OR and endocrine clinic. (See Figure 12) 
 
Figure 12: In vivo Probe Data Collection on a Phantom (gel mimicking thyroid gland) 
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DISCUSSION 
 The goal of the ex vivo ESS study was to demonstrate the ability of ESS to 
differentiate between malignant and benign thyroid conditions and establish ESS spectral 
signatures for each. The second ex vivo study using ESS completed on thyroid specimens 
showed the capability of ESS in predicting malignancy in the thyroid gland with high 
sensitivity and specificity.    
 The ex vivo ESS studies were novel and unique in their application in the thyroid 
gland. The study was the first of its kind and the follow up study provided more rationale 
to further continue to explore and collect data on ESS capabilities of diagnosing 
malignancy in the thyroid. The ex vivo instrument and system had many advantages. The 
system was convenient to use, the probe unit was lightweight and mobile, the procedure 
was minimally invasive and was shown to be effective as an adjunct to FNA and 
compliments cytology evaluation. ESS also provides objective real time assessment of 
the condition of the thyroid, which decreases the waiting time for diagnosis.  Of all other 
optical spectroscopy studies (thyroid or non-thyroid) used for diagnosis, this study has 
shown one of the highest sensitivities and specificities.17 Raman and fluorescence 
spectroscopy have shown various sensitivities and specificities ranging from 80% to 95% 
in colonic dysplasia.43 Conversely, ESS has shown promising results in endoscopic 
diagnosis of Barrett’s esophagus and colonic polyps44, oral cavity lesions, lymph nodes, 
bones, breast cancer for tumor resection/margin, and sentinel lymph node status.29, 45 The 
initial ex vivo study showed higher specificity and positive predictive values than other 
studies.17 The limitations of the first ex vivo study were addressed in our second study. 
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The sample size was increased, a more diverse patient range was included and the need 
for a cut surface to collect ESS measurements was eliminated by designing the in vivo 
probe. While the follow up study was still done on ex vivo specimens, the in vivo study 
was underway and the probes have been manufactured for use in both clinic and the OR.  
The next logical step after compiling significant data on ex vivo thyroid specimens 
was to design an in vivo experiment using the same technology and evaluate its 
effectiveness. An in vivo ESS probe is an ideal instrument as an adjunct to information 
provided by FNA biopsy and cytology. Current in vivo research using optical 
spectroscopy only takes measurements on internal organ surfaces or has not been studied 
in human subjects.46-48 No such technique has been studied in the thyroid.  In vivo ESS is 
a minimally invasive technique that can be done at the same time as the FNA and has 
shown promising results in ex vivo studies.17 Extrapolating the study and techniques to an 
in vivo design has highlighted certain aspects that must be addressed before implementing 
the study on a larger scale. 
Issues with sterilization, mobility and practical data collection should be 
addressed. Sterilization of the non-disposable unit was modeled after current techniques 
used for gastrointestinal (GI) endoscopes.49, 50 The standard sterilization and processing 
of endoscopes are currently per recommendations of the FDA and CDC (Center for 
Disease Control and Prevention). Since the optical probe device will enter thyroid tissue 
that is normally sterile, it requires the highest level of critical disinfection.49 All microbes 
must be destroyed before the device can be re-used. Thus, EtO sterilization was chosen 
for sterilization of the non-disposable units. Sterilization is of utmost importance as it is 
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necessary to prevent contamination of the instrument itself and also prevent infection of 
patients enrolled in the studies. Ensuring complete microbe destruction on the current 
probe unit is essential. Further adjustments to the study design vary depending on 
whether the probe unit will be used in the clinic or in the OR.  
In the Clinic. Study adjustments to accommodate the optical probe data collection 
in the clinic are minor. While obtaining optical probe readings in the clinic is virtually 
identical to performing an FNA, some practical matters must be adjusted. The box and a 
sterilized probe unit should be present in the endocrine clinic to allow for quick patient 
enrollment and data collection at any time. To make data collection and FNA biopsy both 
time efficient and easy for the operator, the box should have a firing switch that can be 
operated using a foot pedal to free the endocrinologist’s hands to use the syringe unit and 
ultrasound device. If this is not feasible, a trained technician should be present to operate 
the computer and elicit data collection commands while the endocrinologist positions the 
needle, deploys the probe and uses ultrasound for guidance. As the ultrasound machine is 
already available for use in the clinic, it is easy to identify smaller nodules and ensure 
that same location is probed and biopsied in the clinic.   
In the OR. Adjustments in the operating room are complicated due to the location 
of the various rooms as well as the sterile environment. Two sets of ORs exist at BMC 
and two units will have to be kept in sterile environments for quick retrieval and data 
collection depending on surgery location. Introduction of microbes or non-sterile 
equipment into the OR is prohibited. Only patients with large and palpable nodules 
should be enrolled for data collection in the OR as ultrasound (US) devices are not 
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generally used during surgery. Furthermore, use of an US device would require billing 
and increase financial costs. Similar to clinic, the box and probe unit will ideally have a 
data collection trigger that does not require an extra hand but can be operated by nurse or 
medical resident if necessary. In the OR, the probe will first be used to obtain data but as 
it provides real time assessment of the thyroid condition, it could be used as detection 
tool for margin assessment in cancer and possibly replace the waiting time necessary for 
frozen section results.  Limitations of conducting the study in the OR include increased 
time spent in the OR and use of resources to do so, difficulties identifying the FNA 
biopsied nodule and lack of complete confidence that FNA and probed location are 
identical. Furthermore, consenting patients for OR data collection may prove to be more 
difficult as most patients have already undergone FNA and may not want to have another 
needle inserted into their thyroid gland. Difficulties in obtaining consent will be 
addressed as they arise.  
In vivo limitations. Some possible limitations of this study include the possibility 
of perfusion affecting the spectra and difficulty ensuring the same exact location was 
probed and biopsied by FNA. For the initial experimental trial, re-usable probes were 
manufactured to conserve financial resources and allow for small-scale data collection. 
The number of pulses used to fire the xenon lamp was adjusted due to the different 
background light present on ex vivo specimens and in vivo thyroid glands. The number of 
pulses was increased significantly due to the darker in vivo environment but the data 
collection and calibration process was identical to ex vivo data collection.  The FNA 
aspirate will have to be done after probe data has been collected as to not interfere with 
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probe reading. Also, the needle itself is easily broken if not handled with care. Careful 
handling of the in vivo instrument is necessary to ensure that the probe remains intact.  
Advantages. While there are limitations to the in vivo probe, the advantages far 
exceed them. The unit is light, can be handheld, readings can be taken at the same time as 
the biopsy, it provides real time assessment in clinic and OR, it does not require the 
expertise of a pathologist, decreased waiting time and patient anxiety for information 
regarding thyroid condition, provides immediate data that can be sent for statistical 
analysis, and would decrease healthcare costs if implemented. With the newer and 
updated box, the algorithm can be trained as data is collected and thus become better at 
predicting malignancy as the sample size for the study increases.    
Changes for larger scale study. If the in vivo probe proves to have accurate 
predictability in diagnosing thyroid malignancy, a large scale in vivo study will need to 
be implemented. The syringe unit will be disposable to allow for easy access to sterile 
and dispensable equipment. The probe fiber itself will still need to be sterilized for re-use. 
Scaling the study to a multi-institutional level will require commitment from investors 
and manufactures. The institutions where the study will be conducted will need to be 
chosen carefully and medical professionals conducting the study will need to be trained 
and educated about ESS and how to operate the probe unit and box. A manufacturer of 
the disposable probe unit will need to be chosen and be able to make enough units to 
meet demands of study enrollment. Following significant results of a large scale in vivo 
trial; commercialization will be the next step. Ideally, the hardware will be designed so 
that it integrates the software and provides analysis in real time. However, to ensure 
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higher quality control, it is possible to have the collected data be sent out by email to a 
central location and analysis will be sent back to institutions. Analyzing data sent out by 
email will allow statisticians to identify variations in data collection and adjust incorrect 
or faulty data collection quicker. The last and final goal of the study will be to create at 
CPT code that will allow medical professionals to provide ESS optical probe diagnosis as 
a tool for patients and bill for it as well. The tool can also be used in other cancers but 
future studies will address the accuracy of it in other organs such as the parathyroid. With 
the current study underway at one institution, selection bias will have to be examined and 
avoided if identified. Conducting the study in multiple institutions and enrolling a diverse 
group of subjects will prevent this.   
 
CONCLUSION 
Current diagnostic techniques used to identify malignant thyroid nodules are subject to 
improvement. Our ex vivo studies showed that ESS correctly identifies malignant nodules 
with high specificity. The in vivo probe was successfully manufactured and preliminary 
experimental data collections are underway. We anticipate similar results from the 
clinical study using the in vivo ESS probe. In the future, use of ESS as a diagnostic tool in 
the thyroid will ultimately increase disease management, decrease risk for patients by 
giving earlier diagnosis and allow medical professionals to provide earlier treatment if 
necessary. Furthermore, if ESS proves to be a practical and accurate tool in the thyroid 
gland, the technology can be extrapolated and studied in other organs such as the 
parathyroid.  
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